Celcuity, Inc. (NASDAQ:CELC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC) have been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $109.8750.

CELC has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $122.00 price objective on shares of Celcuity in a research note on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Stifel Nicolaus upped their price objective on Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Wall Street Zen upgraded Celcuity from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Wells Fargo & Company began coverage on Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target for the company.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 20,000 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares in the company, valued at approximately $10,802,700. This represents a 18.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Richard E. Buller sold 3,000 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at $745,425.20. The trade was a 30.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.77% of the company’s stock.

Institutional Investors Weigh In On Celcuity

Institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its stake in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Celcuity in the 4th quarter worth $42,000. Ogorek Anthony Joseph NY ADV purchased a new stake in Celcuity in the 3rd quarter worth $27,000. US Bancorp DE increased its stake in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares in the last quarter. Finally, NBC Securities Inc. purchased a new stake in Celcuity in the 4th quarter worth $99,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Trading Up 6.6%

NASDAQ:CELC opened at $124.64 on Friday. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. The firm has a market capitalization of $6.03 billion, a price-to-earnings ratio of -32.89 and a beta of 0.41. Celcuity has a one year low of $8.13 and a one year high of $124.64. The business has a fifty day moving average price of $110.16 and a 200-day moving average price of $94.44.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.09. Sell-side analysts forecast that Celcuity will post -2.62 EPS for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.